The role of ultrasonography in follow‐up of effectiveness of Complex Decongestive Therapy (CDT) in different subgroups of patients with breast cancer‐related lymphoedema

2020 ◽  
Author(s):  
Burcu Duyur Çakıt ◽  
F. Figen Ayhan ◽  
Sefa Gümrük Aslan ◽  
Hakan Genç
Keyword(s):  
Breast Cancer ◽  
Complex Decongestive Therapy ◽  
Decongestive Therapy

Complex decongestive therapy for secondary lymphoedema in women after breast cancer treatment

Physiotherapy ◽  
2015 ◽  
Vol 23 (1) ◽  
Author(s):  
Iwona Malicka ◽  
Dawid Marciniak
Keyword(s):  
Breast Cancer ◽  
Fungal Infections ◽  
Compression Therapy ◽  
Lymphatic Drainage ◽  
Skin Care ◽  
Lymph Edema ◽  
Two Phase ◽  
Complex Decongestive Therapy ◽  
Consolidation Phase ◽  
Decongestive Therapy

AbstractSecondary lymph edema occurs in abort 6-40% of women treated for breast cancer. This is not the only an aesthetic problem. Edema makes serious health complications for example recurrent inflammation and rose, limb elephantiasis, which leads to degenerative changes in the joints, nerve plexus damage and angiosarcoma – cancer with poor prognosis. Early diagnosis and implementation of therapy is very important. Too late intervention difficult the rehabilitation and increases the possibility of complications also. The most important in the reduction of swelling and remove the lymph balance is a complex decongestive therapy (CDT): lymphatic drainage, compression therapy, skin care and exercises. Lymphatic drainage results in increased production of the lymph and movement of the lymph. Compression therapy leads to the reduction in the effective pressure ultrafiltration. Skin care is to prevent bacterial and fungal infections. Exercises makes increase muscle pump action and transport of the lymph. CDT consist of two phase: reduction phase and consolidation phase. It is a most popular method of treatment lymph edema around the world. It is most effective therapy also.

Final analysis of the PROMISE-GIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 516-516
Author(s):  
Matteo Lambertini ◽  
Luca Boni ◽  
Andrea Michelotti ◽  
Emanuela Magnolfi ◽  
Alessio Aligi Cogoni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Ovarian Function ◽  
Final Analysis ◽  
Post Treatment ◽  
Phase Iii ◽  
Hormone Receptor Positive ◽  
Premenopausal Patients

516 Background: Current guidelines recommend GnRH agonist (GnRHa) use during chemotherapy (CT) as a strategy to reduce the risk of premature ovarian insufficiency (POI) in premenopausal patients with early breast cancer (EBC). However, no long-term safety data are available raising some concerns on concurrent use of GnRHa during CT in patients with hormone receptor-positive disease. In addition, there is no evidence on the protective role of this strategy in patients with germline BRCA mutations ( mBRCA). Here, we report the final analysis of the PROMISE-GIM6 phase III randomized study, the largest trial addressing the role of GnRHa use during CT in premenopausal EBC patients (Del Mastro et al, JAMA 2011 & Lambertini et al, JAMA 2015). Methods: From October 2003 to January 2008, 281 premenopausal patients aged 18 to 45 years with stage I-III EBC candidates for (neo)adjuvant CT were randomized to receive CT alone or combined with the GnRHa triptorelin. Primary endpoint was incidence of CT-induced POI (defined as amenorrhea and post-menopausal FSH/estradiol levels 1 year following CT). This final analysis reports on post-treatment pregnancies, disease-free survival (DFS) and overall survival (OS). An exploratory descriptive analysis in mBRCA patients is also reported. (ClinicalTrial.gov: NCT00311636) Results: Of the 281 randomized patients (CT+GnRHa arm = 148; CT alone arm = 133), 80% had hormone receptor-positive disease. At the time of this final analysis, 38 (13.5%) patients were lost to follow-up. Median follow-up was 12.4 years (IQR: 11.3-13.2 years). In the CT+GnRHa and CT alone arms, respectively, 9 (10-year cumulative incidence of pregnancy 6.5%, 95% CI 3.5%-12.3%) and 4 (10-year cumulative incidence of pregnancy 3.2%, 95% CI 1.2%-8.3%) patients had a post-treatment pregnancy (HR 2.14, 95% CI 0.66-6.92). No differences in 10-year DFS (72.4% in CT+GnRHa arm vs. 71.2% in CT alone arm: HR 1.16, 95% CI 0.76-1.77) nor in 10-year OS (82.0% in CT+GnRHa arm vs. 85.9% in CT alone arm: HR 1.17, 95% CI 0.67-2.03) were observed. There was no interaction between treatment effect and hormone receptor status. In patients with hormone receptor-positive disease, HR was 1.02 (95% CI 0.63-1.63) for DFS and 1.12 (95% CI 0.59-2.11) for OS. Out of 43 patients tested for BRCA, overall incidence of POI, irrespective of treatment arm, was 20% in mBRCA patients (n = 10) and 12% in patients without mBRCA (n = 33). In mBRCA patients, incidence of POI was 0% and 33% in the CT+GnRHa and CT alone arms, respectively. One post-treatment pregnancy was described in a patient with mBRCA1 in the CT alone arm. Conclusions: The final analysis of the PROMISE-GIM6 trial at a median follow-up of 12.4 years provides reassuring evidence on the safety of GnRHa use during CT as a strategy to preserve ovarian function in premenopausal patients with hormone receptor-positive EBC. Clinical trial information: NCT00311636.

Current Role of Bone Scan with Phosphonates in the Follow-Up of Breast Cancer

Breast Cancer ◽  
2007 ◽  
pp. 227-238
Author(s):  
Lorenzo Maffioli ◽  
Luigia Florimonte ◽  
Luca Pagani ◽  
Ivana Butti ◽  
Isabel Roca
Keyword(s):  
Breast Cancer ◽  
Bone Scan ◽  
Current Role

Role of Bone Scan in Breast Cancer Follow-Up

1997 ◽  
Vol 83 (2) ◽  
pp. 547-549 ◽  
Author(s):  
Lorenzo Maffioli ◽  
Milvia Zambetti ◽  
Maria Rita Castellani ◽  
Emilio Bombardieri
Keyword(s):  
Breast Cancer ◽  
Bone Scan

scholarly journals Patients’ needs and preferences in routine follow-up for early breast cancer; an evaluation of the changing role of the nurse practitioner

2011 ◽  
Vol 37 (9) ◽  
pp. 765-773 ◽  
Author(s):  
M. van Hezewijk ◽  
G.M.C. Ranke ◽  
J.G.H. van Nes ◽  
A.M. Stiggelbout ◽  
G.H. de Bock ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Nurse Practitioner ◽  
Changing Role

Investigating and critically appraising the expression and potential role of androgen receptor in breast carcinoma

2011 ◽  
Vol 7 (1) ◽  
Author(s):  
Mark B. Peter ◽  
Abeer M. Shaaban ◽  
Sree Sundara Rajan ◽  
Loaie Maraqa ◽  
Kieran Horgan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Potential Role ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Continuous Variable ◽  
Endocrine Treatment ◽  
Breast Cancer Death

AbstractThe potential role of the androgen receptor (AR) as a predictive or prognostic factor in breast cancer remains unclear. We aimed to determine the prognostic significance of AR in a cohort of breast carcinomas with long-term follow-up and to critically appraise this in the context of existing literature. Four hundred and eight cases of invasive breast cancer were incorporated into tissue microarrays (TMAs). All received tamoxifen and comprised 108 cases which relapsed and 300 cases which did not. Mean follow-up time for the former was 84 months (range 1–142, SD 38.8) and for the latter was 77 months (range 11–229, SD 49.7). TMAs were immunohistochemically stained with AR and scored as a continuous variable and using the Allred score. AR expression was significantly associated with grade, recurrence on tamoxifen, non-breast cancer death estrogen receptor alpha (ERα) and progesterone receptor (PR). AR correlated significantly with better overall survival (OS) and disease-free survival (DFS) using an Allred cut-off of 4 (log rank=0.0053 and 0.0044, respectively), and 20% positive tumor cells (log rank=0.0027 and 0.0059, respectively). AR expression was additionally associated with a reduced risk of recurrence following endocrine therapy. In summary, AR positive breast tumors have better OS and DFS and are less likely to recur following endocrine treatment.

Associations of depression status and hopelessness with breast cancer: A 24-year follow-up study

2016 ◽  
Vol 22 (10) ◽  
pp. 1322-1331 ◽  
Author(s):  
Amanda M Mitchell ◽  
Patrick Pössel ◽  
Benjamin W Van Voorhees ◽  
William W Eaton
Keyword(s):  
Breast Cancer ◽  
Catchment Area ◽  
Follow Up Study ◽  
Depression Status ◽  
Double Depression ◽  
Extended Duration ◽  
Unexpected Findings ◽  
Epidemiologic Catchment Area Study

This study extended the literature by examining whether three profiles of depression predicted breast cancer status. In 1076 women of the Baltimore Epidemiologic Catchment Area study, depression status and hopelessness were measured at baseline and breast cancer status was ascertained 24 years later. Double depression, but not major depression or dysthymia, was associated with breast cancer. Hopelessness predicted fewer new cases of breast cancer. When double depression and hopelessness were simultaneously entered as predictors, the regression weights of both predictors increased. The role of severe and extended duration depression as well as possible explanations for unexpected findings are discussed.

Sign in / Sign up

Export Citation Format

Share Document